Literature DB >> 16482087

Genetic inactivation of the NMDA receptor NR2A subunit has anxiolytic- and antidepressant-like effects in mice.

Janel M Boyce-Rustay1, Andrew Holmes.   

Abstract

There is growing evidence implicating the glutamate system in the pathophysiology and treatment of mood and anxiety disorders. Glutamatergic neurotransmission is mediated by several receptor subfamilies including multiple NMDA receptor subunits (NR2A-D). However, little is currently understood about the specific roles of NMDA subunits in the mediation of emotional behavior due to a lack of subunit-specific ligands. In the present study, we employed a mouse gene-targeting approach to examine the role of the NR2A subunit in the mediation of anxiety- and depressive-related behaviors. Results showed that NR2A knockout (KO) mice exhibit decreased anxiety-like behavior relative to wild-type littermates (WT) across multiple tests (elevated plus maze, light-dark exploration test, novel open field). NR2A KO mice showed antidepressant-like profiles in the forced swim test and tail suspension test, as compared to WT controls. Locomotor activity in the nonaversive environments of the home cage or a familiar open field were normal in the NR2A KO mice, as were gross neurological and sensory functions, including prepulse inhibition of startle. Taken together, these data demonstrate a selective and robust reduction in anxiety- and depression-related behavior in NMDA receptor NR2A subunit KO mice. Present results support a role for the NR2A subunit in the modulation of emotional behaviors in rodents and provide insight into the role of glutamate in the pathophysiology and treatment of mood and anxiety disorders.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16482087     DOI: 10.1038/sj.npp.1301039

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  87 in total

1.  Subtype selective NMDA receptor antagonists induce recovery of synapses lost following exposure to HIV-1 Tat.

Authors:  A H Shin; H J Kim; S A Thayer
Journal:  Br J Pharmacol       Date:  2012-06       Impact factor: 8.739

2.  Genetic manipulation of STEP reverses behavioral abnormalities in a fragile X syndrome mouse model.

Authors:  S M Goebel-Goody; E D Wilson-Wallis; S Royston; S M Tagliatela; J R Naegele; P J Lombroso
Journal:  Genes Brain Behav       Date:  2012-04-06       Impact factor: 3.449

3.  Selectively silencing GSK-3 isoforms reduces plaques and tangles in mouse models of Alzheimer's disease.

Authors:  David E Hurtado; Laura Molina-Porcel; Jenna C Carroll; Caryn Macdonald; Awo K Aboagye; John Q Trojanowski; Virginia M-Y Lee
Journal:  J Neurosci       Date:  2012-05-23       Impact factor: 6.167

Review 4.  Advancing schizophrenia drug discovery: optimizing rodent models to bridge the translational gap.

Authors:  Judith Pratt; Catherine Winchester; Neil Dawson; Brian Morris
Journal:  Nat Rev Drug Discov       Date:  2012-06-22       Impact factor: 84.694

Review 5.  The Functional and Molecular Properties, Physiological Functions, and Pathophysiological Roles of GluN2A in the Central Nervous System.

Authors:  Yongjun Sun; Xiaokun Cheng; Linan Zhang; Jie Hu; You Chen; Liying Zhan; Zibin Gao
Journal:  Mol Neurobiol       Date:  2016-01-21       Impact factor: 5.590

Review 6.  Glutamatergic targets for new alcohol medications.

Authors:  Andrew Holmes; Rainer Spanagel; John H Krystal
Journal:  Psychopharmacology (Berl)       Date:  2013-09-01       Impact factor: 4.530

7.  Mechanical and cold hypersensitivity in nerve-injured C57BL/6J mice is not associated with fear-avoidance- and depression-related behaviour.

Authors:  F S Hasnie; V C J Wallace; K Hefner; A Holmes; A S C Rice
Journal:  Br J Anaesth       Date:  2007-05-03       Impact factor: 9.166

Review 8.  Realistic expectations of prepulse inhibition in translational models for schizophrenia research.

Authors:  Neal R Swerdlow; Martin Weber; Ying Qu; Gregory A Light; David L Braff
Journal:  Psychopharmacology (Berl)       Date:  2008-06-21       Impact factor: 4.530

9.  Role of major NMDA or AMPA receptor subunits in MK-801 potentiation of ethanol intoxication.

Authors:  Benjamin Palachick; Yi-Chyan Chen; Abigail J Enoch; Rose-Marie Karlsson; Masayoshi Mishina; Andrew Holmes
Journal:  Alcohol Clin Exp Res       Date:  2008-06-28       Impact factor: 3.455

Review 10.  Targeting glutamatergic signaling for the development of novel therapeutics for mood disorders.

Authors:  Rodrigo Machado-Vieira; Giacomo Salvadore; Lobna A Ibrahim; Nancy Diaz-Granados; Carlos A Zarate
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.